A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects

Trial Profile

A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia; Radiation injuries
  • Focus Pharmacodynamics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 21 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top